ZimVie Reports Second Quarter 2025 Financial Results
- Recently entered into definitive agreement to be acquired by ARCHIMED for $19.00 in cash per share
- Net Sales from Continuing Operations of $116.7 million
- Net Loss from Continuing Operations of $(3.8) million; Net Loss margin of (3.3)%
- Adjusted EBITDA[1] from Continuing Operations of $17.5 million; Adjusted EBITDA[1] margin of 15.0%
-
GAAP diluted EPS from Continuing Operations of $(0.14) and adjusted diluted EPS[1] from Continuing Operations of $0.26
PALM BEACH GARDENS, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today reported financial results for the quarter ended June 30, 2025.
“Our results this quarter reflect the strength of our people and their unwavering commitment to executing our strategy and delivering for our customers and stakeholders,” said Vafa Jamali, Chairman of the Board and Chief Executive Officer. “I would like to thank our entire team for their continued hard work and dedication.”
Second Quarter 2025 Financial Results: Continuing Operations
Net sales for the second quarter of 2025 were $116.7 million, a decrease of (0.1)% on a reported basis and (2.1)% in constant currency[1], versus the second quarter of 2024.
Net loss for the second quarter of 2025 was $(3.8) million, an improvement of $5.7 million versus a net loss of $(9.6) million in the second quarter of 2024. Net loss margin for the second quarter of 2025 was (3.3)% of net sales, an improvement of 490 basis points versus a net loss margin of (8.2)% in the second quarter of 2024.
Adjusted net income[1] for the second quarter of 2025 was $7.2 million, an increase of $3.6 million versus the second quarter of 2024.
Basic and diluted EPS were $(0.14) and adjusted diluted EPS[1] was $0.26 for the second quarter of 2025. Weighted average shares outstanding for both basic and adjusted diluted EPS was 28.0 million.
Adjusted EBITDA[1] for the second quarter of 2025 was $17.5 million, or 15.0% of net sales, an increase of $1.6 million or 150 basis points versus the second quarter of 2024.
[1] This is a non-GAAP financial measure. Refer to “Note on Non-GAAP Financial Measures” and the reconciliations in this release for further information.
Pending Acquisition by Affiliate of ARCHIMED
On July 21, 2025, ZimVie issued a press release announcing ZimVie’s entry into a definitive agreement pursuant to which ZimVie will be acquired by an affiliate of ARCHIMED (“ARCHIMED”) for $19.00 in cash per share. A copy of that press release is accessible by visiting the “Investor Relations” section of ZimVie’s website.
The transaction is expected to close by year-end 2025, subject to the satisfaction of customary closing conditions, including approval by ZimVie’s stockholders and receipt of applicable regulatory approvals. Upon completion of the transaction, ZimVie will become a privately held company and shares of ZimVie common stock will no longer be listed or publicly traded on the NASDAQ stock exchange. Due to the pending transaction, ZimVie will not host a conference call for the second quarter and ZimVie is withdrawing fiscal 2025 guidance. ZimVie's previous financial guidance should not be relied upon.
For further details on quarterly performance, please refer to ZimVie’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which is expected to be filed today with the Securities and Exchange Commission (the "SEC").
About ZimVie
ZimVie is a global life sciences leader in the dental implant market that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to support dental tooth replacement and restoration procedures. From its headquarters in Palm Beach Gardens, Florida, and additional facilities around the globe, ZimVie works to improve smiles, function, and confidence in daily life by offering comprehensive tooth replacement solutions, including trusted dental implants, biomaterials, and digital workflow solutions. As a worldwide leader in this space, ZimVie is committed to advancing clinical science and technology foundational to restoring daily life. For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.
Note on Non-GAAP Financial Measures
This press release includes non-GAAP financial measures that differ from financial measures calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These non-GAAP financial measures may not be comparable to similar measures reported by other companies and should be considered in addition to, and not as a substitute for, or superior to, other measures prepared in accordance with GAAP.
Sales change information in this press release is presented on a GAAP (reported) basis and on a constant currency basis. Constant currency percentage changes exclude the effects of foreign currency exchange rates. They are calculated by translating current and prior-period sales from Continuing Operations at the same predetermined exchange rate. The translated results are then used to determine year-over-year percentage increases or decreases.
Net income (loss) and diluted earnings (loss) per share in this press release are presented on a GAAP (reported) basis and on an adjusted basis. Adjusted net income (loss) and adjusted diluted earnings (loss) per share exclude the effects of certain items, which are detailed in the reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures presented later in this press release.
Adjusted EBITDA is a non-GAAP financial measure provided in this press release for certain periods and is calculated by excluding certain items from net income (loss) from Continuing Operations on a GAAP basis, as detailed in the reconciliations presented later in this press release. Adjusted EBITDA margin is Adjusted EBITDA divided by net sales from Continuing Operations for the applicable period.
Adjusted cost of products sold (excluding intangible asset amortization), adjusted R&D and adjusted SG&A (on an actual basis and as a percentage of sales) are non-GAAP financial measures provided in this press release for certain periods and are calculated by excluding the effects of certain items from cost of products sold (excluding intangible asset amortization), R&D and SG&A, respectively, on a GAAP basis, as detailed in the reconciliations presented later in this press release.
Reconciliations of these non-GAAP measures to the most directly comparable GAAP financial measures are included in this press release.
Management uses non-GAAP financial measures internally to evaluate the performance of the business. Additionally, management believes these non-GAAP measures provide meaningful incremental information to investors to consider when evaluating the performance of the company. Management believes these measures offer the ability to make period-to-period comparisons that are not impacted by certain items that can cause dramatic changes in reported income (loss), but that do not impact the fundamentals of our operations. The non-GAAP measures enable the evaluation of operating results and trend analysis by allowing a reader to better identify operating trends that may otherwise be masked or distorted by these types of items that are excluded from the non-GAAP measures.
Participants in the Solicitation
ZimVie and its directors, executive officers and other members of management and employees, under SEC rules, may be deemed to be “participants” in the solicitation of proxies from stockholders of ZimVie in connection with the proposed transaction with Zamboni Parent, Inc., an affiliate of ARCHIMED. Information about ZimVie’s directors and executive officers is set forth in ZimVie’s Proxy Statement on Schedule 14A for its 2025 Annual Meeting of Shareholders, which was filed with the SEC on March 25, 2025 (the “2025 Proxy”) (and available here). Please refer to the sections entitled “Compensation of Non-Employee Directors,” “Executive Compensation” and “Security Ownership of Directors and Executive Officers” in the 2025 Proxy. To the extent holdings of ZimVie’s securities by its directors or executive officers have changed since the amounts set forth in the 2025 Proxy, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC, including the Form 4s filed by: Richard Heppenstall on March 11, 2025 and May 19, 2025; Vafa Jamali on March 11, 2025, March 27, 2025, March 27, 2025, April 3, 2025 and May 19, 2025; Indraneel Kanaglekar on March 11, 2025, May 19, 2025 and July 3, 2025; Heather Kidwell on March 11, 2025 and May 19, 2025; Richard Kuntz on April 2, 2025, May 9, 2025 and July 2, 2025; Vinit K. Asar on May 9, 2025; Sally Crawford on May 9, 2025; and Karen Matusinec on May 9, 2025. Additional information concerning the interests of ZimVie’s participants in the solicitation, which may, in some cases, be different than those of ZimVie’s stockholders generally, will be set forth in ZimVie’s proxy statement relating to the proposed transaction when it becomes available.
Additional Important Information
This press release may be deemed to be solicitation material in respect of the proposed acquisition of ZimVie by Zamboni Parent, Inc., an affiliate of ARCHIMED. In connection with the proposed transaction, ZimVie intends to file relevant materials with the SEC, including ZimVie’s proxy statement in preliminary and definitive form. INVESTORS AND STOCKHOLDERS OF ZIMVIE ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING ZIMVIE’S PROXY STATEMENT (IF AND WHEN AVAILABLE), BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and stockholders are or will be able to obtain the documents (if and when available) free of charge at the SEC’s website at www.sec.gov, or free of charge from ZimVie in the “Investor Relations” section of ZimVie’s website, which may be accessed at https://investor.zimvie.com, or upon request from ZimVie’s Investor Relations contacts.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including, among others, any statements about our expectations, plans, intentions, strategies or prospects. We generally use the words “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “assumes,” “guides,” “targets,” “forecasts,” “sees,” “seeks,” “should,” “could,” “would,” “predicts,” “potential,” “strategy,” “future,” “opportunity,” “work toward,” “intends,” “guidance,” “confidence,” “positioned,” “design,” “strive,” “continue,” “track,” “look forward to” and similar expressions to identify forward-looking statements. All statements other than statements of historical or current fact are, or may be deemed to be, forward-looking statements. Such statements are based upon the current beliefs, expectations and assumptions of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially from the forward-looking statements. These risks, uncertainties and changes in circumstances include, but are not limited to: the risk that the proposed transaction may not be completed in a timely manner or at all; the failure to receive, on a timely basis or otherwise, the required approval of the proposed transaction by our stockholders; the possibility that any or all of the various other conditions to the consummation of the proposed transaction may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations, or restrictions placed on such approvals); the possibility that competing offers or acquisition proposals for ZimVie will be made; the occurrence of any event, change, or other circumstance that could give rise to the termination of the definitive agreement relating to the proposed transaction, including in circumstances which would require us to pay a termination fee; the effect of the pendency of the proposed transaction on our ability to attract, motivate, or retain key executives and employees; the effect of the pendency of the proposed transaction on our ability to maintain relationships with our customers, suppliers, and other business counterparties; the effect of the pendency of the proposed transaction on our operating results and business generally; the risk that the proposed transaction will divert management’s attention from our ongoing business operations; the risk that our stock price may decline significantly if the proposed transaction is not consummated; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products, including impacts from tariffs; pricing pressures from competitors, customers, dental practices and insurance providers; changes in customer demand for our products and services caused by demographic changes or other factors; challenges relating to changes in and compliance with governmental laws and regulations affecting our United States ("U.S.") and international businesses, including regulations of the U.S. Food and Drug Administration and foreign government regulators, such as more stringent requirements for regulatory clearance of products; competition; the impact of healthcare reform measures; reductions in reimbursement levels by third-party payors; cost containment efforts sponsored by government agencies, legislative bodies, the private sector and healthcare group purchasing organizations, including the volume-based procurement process in China; control of costs and expenses; dependence on a limited number of suppliers for key raw materials and outsourced activities; the ability to obtain and maintain adequate intellectual property protection; breaches or failures of our information technology systems or products, including by cyberattack, unauthorized access or theft; the ability to retain the independent agents and distributors who market our products; our ability to attract, retain and develop the highly skilled employees we need to support our business; the effect of mergers and acquisitions on our relationships with customers, suppliers and lenders and on our operating results and businesses generally; a determination by the Internal Revenue Service that the distribution of our shares of common stock by Zimmer Biomet Holdings, Inc. in 2022 (the "distribution") or certain related transactions should be treated as taxable transactions; the ability to form and implement alliances; changes in tax obligations arising from tax reform measures, including European Union rules on state aid, or examinations by tax authorities; product liability, intellectual property and commercial litigation losses; changes in general industry and market conditions, including domestic and international growth rates; changes in general domestic and international economic conditions, including inflation and interest rate and currency exchange rate fluctuations; the effects of global pandemics and other adverse public health developments on the global economy, our business and operations and the business and operations of our suppliers and customers, including the deferral of elective procedures and our ability to collect accounts receivable; and the impact of the ongoing financial and political uncertainty on countries in the Euro zone on the ability to collect accounts receivable in affected countries.
Media Contact Information:
ZimVie Inc.
Grace Flowers • Grace.Flowers@ZimVie.com
(561) 319-6130
Investor Contact Information:
Gilmartin Group LLC
Webb Campbell • Webb@gilmartinir.com
|
ZIMVIE INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) (unaudited) |
||||||||||||||||
| For the Three Months Ended June 30, |
For the Six Months Ended June 30, |
|||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net sales | $ | 116,662 | $ | 116,811 | $ | 228,659 | $ | 235,006 | ||||||||
| Cost of products sold, excluding intangible asset amortization | (41,354 | ) | (43,517 | ) | (79,303 | ) | (87,775 | ) | ||||||||
| Intangible asset amortization | (6,183 | ) | (5,999 | ) | (12,215 | ) | (12,022 | ) | ||||||||
| Research and development | (5,662 | ) | (6,579 | ) | (11,033 | ) | (13,359 | ) | ||||||||
| Selling, general and administrative | (59,573 | ) | (62,384 | ) | (118,558 | ) | (122,714 | ) | ||||||||
| Restructuring and other cost reduction initiatives | (83 | ) | (398 | ) | (1,515 | ) | (2,977 | ) | ||||||||
| Acquisition, integration, divestiture and related | (2,516 | ) | (4,621 | ) | (3,964 | ) | (5,657 | ) | ||||||||
| Operating Expenses | (115,371 | ) | (123,498 | ) | (226,588 | ) | (244,504 | ) | ||||||||
| Operating Profit (Loss) | 1,291 | (6,687 | ) | 2,071 | (9,498 | ) | ||||||||||
| Other income, net | 766 | 3,010 | 2,450 | 2,701 | ||||||||||||
| Interest income | 2,046 | 1,965 | 4,081 | 2,472 | ||||||||||||
| Interest expense | (3,836 | ) | (5,066 | ) | (7,887 | ) | (9,940 | ) | ||||||||
| Income (loss) from continuing operations before income taxes | 267 | (6,778 | ) | 715 | (14,265 | ) | ||||||||||
| Provision for income taxes from continuing operations | (4,115 | ) | (2,775 | ) | (7,188 | ) | (6,849 | ) | ||||||||
| Net Loss from Continuing Operations of ZimVie Inc. | (3,849 | ) | (9,553 | ) | (6,474 | ) | (21,114 | ) | ||||||||
| (Loss) income from discontinued operations, net of tax | (99 | ) | 5,539 | 1,055 | 9,339 | |||||||||||
| Net Loss of ZimVie Inc. | $ | (3,947 | ) | $ | (4,014 | ) | $ | (5,418 | ) | $ | (11,775 | ) | ||||
| Basic (Loss) Earnings Per Common Share: | ||||||||||||||||
| Continuing operations | $ | (0.14 | ) | $ | (0.35 | ) | $ | (0.23 | ) | $ | (0.77 | ) | ||||
| Discontinued operations | - | 0.20 | 0.04 | 0.34 | ||||||||||||
| Net Loss | $ | (0.14 | ) | $ | (0.15 | ) | $ | (0.19 | ) | $ | (0.43 | ) | ||||
| Diluted (Loss) Earnings Per Common Share: | ||||||||||||||||
| Continuing operations | $ | (0.14 | ) | $ | (0.35 | ) | $ | (0.23 | ) | $ | (0.77 | ) | ||||
| Discontinued operations | - | 0.20 | 0.04 | 0.34 | ||||||||||||
| Net Loss | $ | (0.14 | ) | $ | (0.15 | ) | $ | (0.19 | ) | $ | (0.43 | ) | ||||
|
ZIMVIE INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except per share data) (unaudited) |
||||||||
| As of | ||||||||
| June 30, 2025 | December 31, 2024 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 70,176 | $ | 74,974 | ||||
| Accounts receivable, net of allowance for credit losses of $2,004 and $2,088, respectively | 84,519 | 65,211 | ||||||
| Inventories | 84,447 | 75,018 | ||||||
| Prepaid expenses and other current assets | 21,067 | 23,295 | ||||||
| Current assets of discontinued operations | — | 18,787 | ||||||
| Total Current Assets | 260,209 | 257,285 | ||||||
| Property, plant and equipment, net of accumulated depreciation of $136,256 and $126,620, respectively | 48,799 | 47,268 | ||||||
| Goodwill | 266,232 | 257,605 | ||||||
| Intangible assets, net | 86,462 | 92,734 | ||||||
| Note receivable | 67,893 | 64,643 | ||||||
| Other assets | 28,629 | 26,611 | ||||||
| Noncurrent assets of discontinued operations | — | 7,528 | ||||||
| Total Assets | $ | 758,224 | $ | 753,674 | ||||
| LIABILITIES AND EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 41,684 | $ | 32,958 | ||||
| Income taxes payable | 2,249 | 3,263 | ||||||
| Other current liabilities | 65,680 | 62,905 | ||||||
| Current liabilities of discontinued operations | — | 34,818 | ||||||
| Total Current Liabilities | 109,613 | 133,944 | ||||||
| Deferred income taxes | 109 | — | ||||||
| Lease liability | 10,070 | 8,218 | ||||||
| Other long-term liabilities | 4,845 | 9,232 | ||||||
| Non-current portion of debt | 220,786 | 220,451 | ||||||
| Noncurrent liabilities of discontinued operations | — | 122 | ||||||
| Total Liabilities | 345,423 | 371,967 | ||||||
| Commitments and Contingencies | ||||||||
| Stockholders' Equity: | ||||||||
| Common stock, $0.01 par value, 150,000 shares authorized Shares, issued and outstanding, of 28,197 and 27,667, respectively |
282 | 277 | ||||||
| Preferred stock, $0.01 par value, 15,000 shares authorized, 0 shares issued and outstanding | — | — | ||||||
| Additional paid in capital | 945,487 | 938,630 | ||||||
| Accumulated deficit | (472,057 | ) | (466,639 | ) | ||||
| Accumulated other comprehensive loss | (60,911 | ) | (90,561 | ) | ||||
| Total Stockholders' Equity | 412,801 | 381,707 | ||||||
| Total Liabilities and Stockholders' Equity | $ | 758,224 | $ | 753,674 | ||||
|
ZIMVIE INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited) |
|||||||
| For the Six Months Ended June 30, |
|||||||
| 2025 | 2024 | ||||||
| Cash flows used in operating activities: | |||||||
| Net loss of ZimVie Inc. | $ | (5,418 | ) | $ | (11,775 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Depreciation and amortization | 17,281 | 16,917 | |||||
| Share-based compensation | 7,571 | 9,150 | |||||
| Deferred income tax provision | 1,290 | (3,458 | ) | ||||
| (Gain) loss on disposal of fixed assets | (200 | ) | 430 | ||||
| Other non-cash items | 372 | 2,370 | |||||
| Adjustment of spine disposal group to fair value | — | (22,427 | ) | ||||
| Changes in operating assets and liabilities | |||||||
| Income taxes | 869 | 5,706 | |||||
| Accounts receivable | (14,391 | ) | (8,648 | ) | |||
| Inventories | (4,615 | ) | 10,580 | ||||
| Prepaid expenses and other current assets | 4,064 | (927 | ) | ||||
| Accounts payable and accrued liabilities | (14,524 | ) | (6,206 | ) | |||
| Other assets and liabilities | (2,981 | ) | (187 | ) | |||
| Net cash used in operating activities | (10,682 | ) | (8,475 | ) | |||
| Cash flows (used in) provided by investing activities | |||||||
| Additions to instruments | — | (1,316 | ) | ||||
| Additions to other property, plant and equipment | (3,078 | ) | (2,093 | ) | |||
| Cash paid for acquisitions | (3,282 | ) | — | ||||
| Proceeds from sale of spine disposal group, net of cash disposed | — | 291,123 | |||||
| Other investing activities | (3,017 | ) | (2,015 | ) | |||
| Net cash used in investing activities | (9,377 | ) | 285,699 | ||||
| Cash flows used in financing activities: | |||||||
| Payments on debt | — | (275,000 | ) | ||||
| Payments related to tax withholding for share-based compensation | (709 | ) | (1,670 | ) | |||
| Net cash used in financing activities | (709 | ) | (276,670 | ) | |||
| Effect of exchange rates on cash and cash equivalents | 14,372 | (5,627 | ) | ||||
| Decrease in cash and cash equivalents | (6,396 | ) | (5,073 | ) | |||
| Cash and cash equivalents, beginning of year | 76,572 | 87,768 | |||||
| Cash and cash equivalents, end of period | $ | 70,176 | $ | 82,695 | |||
| Presentation includes cash of both continuing and discontinued operations | |||||||
|
RECONCILIATION OF CONSTANT CURRENCY NET SALES Continuing Operations ($ in thousands) |
|||||||||||||||||||
| For the Three Months Ended June 30, |
|||||||||||||||||||
| 2025 | 2024 | Change (%) | Foreign Exchange Impact | Constant Currency % Change | |||||||||||||||
| United States | $ | 67,958 | $ | 69,316 | (2.0 | %) | 0.0 | % | (2.0 | %) | |||||||||
| International | 48,704 | 47,495 | 2.5 | % | 5.0 | % | (2.5 | %) | |||||||||||
| Net Sales | $ | 116,662 | $ | 116,811 | (0.1 | %) | 2.0 | % | (2.1 | %) | |||||||||
| For the Six Months Ended June 30, |
|||||||||||||||||||
| 2025 | 2024 | Change (%) | Foreign Exchange Impact | Constant Currency % Change | |||||||||||||||
| United States | $ | 133,791 | $ | 137,064 | (2.4 | %) | 0.0 | % | (2.4 | %) | |||||||||
| International | 94,868 | 97,942 | (3.1 | %) | 1.0 | % | (4.1 | %) | |||||||||||
| Net Sales | $ | 228,659 | $ | 235,006 | (2.7 | %) | 0.4 | % | (3.1 | %) | |||||||||
|
RECONCILIATION OF ADJUSTED NET INCOME AND DILUTED EPS Continuing Operations ($ in thousands, except per share data) |
|||||||||||||||||||
| For the Three Months Ended June 30, 2025 | |||||||||||||||||||
| Net Sales | Cost of products sold, excluding intangible asset amortization | Operating expenses, excluding cost of products sold | Operating Income | Net (Loss) Income | Diluted EPS | ||||||||||||||
| Reported | $ | 116,662 | $ | (41,354 | ) | $ | (74,017 | ) | $ | 1,291 | $ | (3,849 | ) | $ | (0.14 | ) | |||
| Restructuring and other cost reduction initiatives [1] | - | - | 83 | 83 | 83 | - | |||||||||||||
| Acquisition, integration, divestiture and related [2] | - | - | 2,516 | 2,516 | 2,516 | 0.09 | |||||||||||||
| Intangible asset amortization | - | - | 6,183 | 6,183 | 6,183 | 0.22 | |||||||||||||
| Other charges [3] | - | 344 | 83 | 427 | 427 | 0.02 | |||||||||||||
| Share-based compensation modification [4] | - | - | 249 | 249 | 249 | 0.01 | |||||||||||||
| Blended global statutory tax rate adjustment [5] | - | - | - | - | 1,586 | 0.06 | |||||||||||||
| Adjusted | $ | 116,662 | $ | (41,010 | ) | $ | (64,903 | ) | $ | 10,749 | $ | 7,195 | $ | 0.26 | |||||
| For the Three Months Ended June 30, 2024 | |||||||||||||||||||
| Net Sales | Cost of products sold, excluding intangible asset amortization | Operating expenses, excluding cost of products sold | Operating (Loss) Income | Net (Loss) Income | Diluted EPS | ||||||||||||||
| Reported | $ | 116,811 | $ | (43,517 | ) | $ | (79,981 | ) | $ | (6,687 | ) | $ | (9,553 | ) | $ | (0.35 | ) | ||
| Restructuring and other cost reduction initiatives [1] | - | - | 398 | 398 | 398 | 0.01 | |||||||||||||
| Acquisition, integration, divestiture and related [2] | - | - | 4,621 | 4,621 | 4,621 | 0.17 | |||||||||||||
| Intangible asset amortization | - | - | 5,999 | 5,999 | 5,999 | 0.22 | |||||||||||||
| European Union medical device regulation [6] | - | - | 311 | 311 | 311 | 0.01 | |||||||||||||
| Other charges [3] | - | 287 | - | 287 | 287 | 0.01 | |||||||||||||
| Blended global statutory tax rate adjustment [5] | - | - | - | - | 1,517 | 0.06 | |||||||||||||
| Adjusted | $ | 116,811 | $ | (43,230 | ) | $ | (68,652 | ) | $ | 4,929 | $ | 3,580 | $ | 0.13 | |||||
[1] Restructuring activities to optimize our organization for future success based on the current business environment and sale of the spine business, primarily related to employee termination benefits.
[2] Acquisition, integration, divestiture and related expenses for the three months ended June 30, 2025 primarily include transaction costs related to the evaluation of strategic alternatives for our portfolio ($2.6 million). Acquisition, integration, divestiture and related expenses for the three months ended June 30, 2024 primarily include professional services fees related to the sale of the spine segment ($3.3 million) and the evaluation of strategic alternatives for our portfolio ($1.3 million).
[3] For the three months ended June 30, 2025, other charges represent amortization of the step-up to fair value of property, plant and equipment and inventory resulting from prior acquisitions ($0.3 million, included in cost of products sold) and regulatory costs incurred to change the manufacturer of record as required by our separation from Zimmer Biomet Holdings, Inc. after initial compliance with the European Union Medical Device Regulation ($0.1 million, included in operating expenses). For the three months ended June 30, 2024, other charges represent amortization of the step-up to fair value of property, plant and equipment resulting from prior acquisitions ($0.3 million, included in cost of products sold).
[4] Net impact to share-based compensation expense of converting outstanding restricted stock units (“RSUs”) with performance-based metrics based on the consolidated results of the spine and dental segments into time-based RSUs following the sale of the spine segment.
[5] Application of our estimated blended global statutory tax rate for each period presented to adjusted pre-tax income, which was determined in consideration of current tax law in the jurisdictions in which we operate and current expected adjusted pre-tax income. Actual reported tax expense will ultimately be based on GAAP earnings and may differ from the estimated blended global statutory tax rate due to a variety of factors, including the resolutions of discrete or non-operational tax impacts, changes in tax law, the ability to realize deferred tax assets and the tax impact of certain reconciling items that are excluded in determining Adjusted Net Income (Loss) and Adjusted EPS.
[6] Expenses incurred for initial compliance with the European Union Medical Device Regulation for previously-approved products
|
RECONCILIATION OF ADJUSTED EBITDA Continuing Operations ($ in thousands) |
|||||||||||||||
| For the Three Months Ended June 30, |
For the Six Months Ended June 30, |
||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Net Sales | $ | 116,662 | $ | 116,811 | $ | 228,659 | $ | 235,006 | |||||||
| Net Loss | $ | (3,849 | ) | $ | (9,553 | ) | $ | (6,474 | ) | $ | (21,114 | ) | |||
| Interest expense, net | 1,790 | 3,101 | 3,806 | 7,468 | |||||||||||
| Income tax provision | 4,115 | 2,775 | 7,188 | 6,849 | |||||||||||
| Depreciation and amortization | 8,626 | 8,487 | 17,281 | 16,917 | |||||||||||
| EBITDA | 10,682 | 4,810 | 21,801 | 10,120 | |||||||||||
| Share-based compensation | 4,073 | 5,677 | 7,571 | 9,150 | |||||||||||
| Restructuring and other cost reduction initiatives [1] | 83 | 398 | 1,515 | 2,977 | |||||||||||
| Acquisition, integration, divestiture and related [2] | 2,516 | 4,621 | 3,964 | 5,657 | |||||||||||
| European Union medical device regulation [3] | - | 311 | - | 712 | |||||||||||
| Other charges [4] | 98 | - | 160 | - | |||||||||||
| Adjusted EBITDA | $ | 17,452 | $ | 15,817 | $ | 35,011 | $ | 28,616 | |||||||
| Net Loss Margin [5] | (3.3 | %) | (8.2 | %) | (2.8 | %) | (9.0 | %) | |||||||
| Adjusted EBITDA Margin [6] | 15.0 | % | 13.5 | % | 15.3 | % | 12.2 | % | |||||||
[1] Restructuring activities to optimize our organization for future success based on the current business environment and sale of the spine business, primarily related to employee termination benefits.
[2] Acquisition, integration, divestiture and related expenses for the three months ended June 30, 2025 primarily include transaction costs related to the evaluation of strategic alternatives for our portfolio ($2.6 million). Acquisition, integration, divestiture and related expenses for the three months ended June 30, 2024 primarily include professional services fees related to the sale of the spine segment ($3.3 million) and the evaluation of strategic alternatives for our portfolio ($1.3 million). Acquisition, integration, divestiture and related expenses for the six months ended June 30, 2025 include professional services fees related to the evaluation of strategic alternatives for our portfolio ($2.9 million) and the sale of the spine segment ($1.1 million). Acquisition, integration, divestiture and related expenses for the six months ended June 30, 2024 primarily include professional services fees related to the sale of the spine segment ($4.4 million) the evaluation of strategic alternatives for our portfolio ($1.3 million).
[3] Expenses incurred for initial compliance with the European Union Medical Device Regulation for previously-approved products.
[4] For the three and six months ended June 30, 2025, other charges represents regulatory costs incurred to change the manufacturer of record as required by our separation from Zimmer Biomet Holdings, Inc. after initial compliance with the European Union Medical Device Regulation.
[5] Net Loss Margin is calculated as Net Loss divided by Net Sales for the applicable period.
[6] Adjusted EBITDA Margin is Adjusted EBITDA divided by Net Sales for the applicable period.
|
RECONCILIATION OF COST OF PRODUCTS SOLD (excluding intangible asset amortization), R&D and SG&A Continuing Operations ($ in thousands) |
|||||||||||||||||||||||||||||||
| For the Three Months Ended June 30, |
Percentage of Third Party Net Sales |
For the Six Months Ended June 30, |
Percentage of Third Party Net Sales |
||||||||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||||
| Cost of products sold, excluding intangible asset amortization | $ | (41,354 | ) | $ | (43,517 | ) | (35.4 | %) | (37.3 | %) | $ | (79,303 | ) | $ | (87,775 | ) | (34.7 | %) | (37.4 | %) | |||||||||||
| Other charges [1] | 344 | 287 | 0.2 | % | 0.3 | % | 658 | 573 | 0.3 | % | 0.3 | % | |||||||||||||||||||
| Adjusted cost of products sold, excluding intangible asset amortization | $ | (41,010 | ) | $ | (43,230 | ) | (35.2 | %) | (37.0 | %) | $ | (78,645 | ) | $ | (87,202 | ) | (34.4 | %) | (37.1 | %) | |||||||||||
| 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||||
| Research and development | $ | (5,662 | ) | $ | (6,579 | ) | (4.9 | %) | (5.6 | %) | $ | (11,033 | ) | $ | (13,359 | ) | (4.8 | %) | (5.7 | %) | |||||||||||
| European union medical device regulation [2] | - | 311 | 0.0 | % | 0.3 | % | - | 712 | 0.0 | % | 0.4 | % | |||||||||||||||||||
| Adjusted research and development | $ | (5,662 | ) | $ | (6,268 | ) | (4.9 | %) | (5.4 | %) | $ | (11,033 | ) | $ | (12,647 | ) | (4.8 | %) | (5.4 | %) | |||||||||||
| 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||||
| Selling, general and administrative | $ | (59,573 | ) | $ | (62,384 | ) | (51.1 | %) | (53.4 | %) | $ | (118,558 | ) | $ | (122,714 | ) | (51.8 | %) | (52.2 | %) | |||||||||||
| Other charges [1] | 83 | - | 0.1 | % | 0.0 | % | 117 | - | 0.0 | % | 0.0 | % | |||||||||||||||||||
| Shared-based compensation modification [3] | 249 | - | 0.2 | % | 0.0 | % | 500 | - | 0.2 | % | 0.0 | % | |||||||||||||||||||
| Adjusted selling, general and administrative | $ | (59,241 | ) | $ | (62,384 | ) | (50.8 | %) | (53.4 | %) | $ | (117,941 | ) | $ | (122,714 | ) | (51.6 | %) | (52.2 | %) | |||||||||||
[1] For the three months ended June 30, 2025, other charges represent amortization of the step-up to fair value of property, plant and equipment and inventory resulting from prior acquisitions ($0.3 million, included in cost of products sold) and regulatory costs incurred to change the manufacturer of record as required by our separation from Zimmer Biomet Holdings, Inc. after initial compliance with the European Union Medical Device Regulation ($0.1 million, included in SG&A). For the three months ended June 30, 2024, other charges represent amortization of the step-up to fair value of property, plant and equipment resulting from prior acquisitions ($0.3 million, included in cost of products sold). For the six months ended June 30, 2025, other charges represent amortization of the step-up to fair value of property, plant and equipment and inventory resulting from prior acquisitions ($0.7 million, included in cost of products sold) and regulatory costs incurred to change the manufacturer of record as required by our separation from Zimmer Biomet Holdings, Inc. after initial compliance with the European Union Medical Device Regulation ($0.1 million, included in SG&A). For the six months ended June 30, 2024, other charges represent amortization of the step-up to fair value of property, plant and equipment resulting from prior acquisitions ($0.6 million, included in cost of products sold)
[2] Expenses incurred for initial compliance with the European Union Medical Device Regulation for previously-approved products.
[3] Net impact to share-based compensation expense of converting outstanding restricted stock units (“RSUs”) with performance-based metrics based on the consolidated results of the spine and dental segments into time-based RSUs following the sale of the spine segment.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
